Home > Insider Trading > Filing (0001140361-17-001760)

Filing Details

Accession Number:: 0001140361-17-001760
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-12 21:59:16
Reporting Period:: 2017-01-10

Filing Date:: 2017-01-12
Accepted Time:: 2017-01-12 21:59:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380187	Daniel Abdun-Nabi	400 Professional Dr, Suite 400 Gaithersburg MD 20879	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-08-01	1,979	$0.00	172,945	No	4	J	Direct
Common Stock	Acquisiton	2016-08-01	3,032	$0.00	175,977	No	4	J	Direct
Common Stock	Acquisiton	2016-08-01	3,419	$0.00	179,396	No	4	J	Direct
Common Stock	Acquisiton	2017-01-10	38,006	$14.51	217,402	No	4	M	Direct
Common Stock	Disposition	2017-01-10	28,240	$31.28	189,162	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	J	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	3,662	$0.00	3,662	$14.51
Common Stock	Stock Option (Right to buy)	Acquisiton	2017-01-10	38,006	$0.00	38,006	$14.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,668		2017-03-08	No	4	J	Direct
3,662		2017-03-08	No	4	M	Direct

Footnotes

In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017.
In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.
In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive.
Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award.
Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off.
The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.